Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-08-29
2011-10-11
Henley, III, Raymond (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08034828
ABSTRACT:
The present invention thus relates to the use of 1,2,3-substituted indolizine derivatives in the preparation of medicaments of use in the treatment of diseases related to pathological choroidal angiogenesis, which derivatives correspond to the following general formula (I):
REFERENCES:
patent: 7442708 (2008-10-01), Badorc et al.
Ozaki, et al., Basic Fibroblast Growth Factor is Neither Necessary Nor Sufficient for the Development of retinal Neovascularization, Amer. J. of Pathology; Sep. 1998; vol. 153,No. 3; pp. 757-765.
Rousseau, et al., Involvement of Fibroblast Growth Factors in Choroidal Angiogenesis and retinal Vascularization, Experimental Eye Research; Aug. 2003; vol. 77,No. 2; pp. 147-156.
Rousseau, et al., Neural and Angiogenic Defects in Eyes of Transgenic Mice Expressing a Dominant-negative FGF Receptor in the Pigmented Cells, Experimental Eye Research; Oct. 2000; vol. 71,No. 4; pp. 395-404.
Soubrane, et al., Basic Fibroblast Growth factor Experimentally Induced Choroidal Angiogenesis in the Minipig, Current Eye Research; Mar. 1994; vol.13,No. 3; pp. 183-195.
Tobe, et al., Targeted Disruption of the FGF2 Gene Does Not Prevent Choroidal Neovascularization in a Murien Model., Amer. J. of Pathology; Nov. 1998; vol. 153,No. 5; pp. 1641-1646.
Yamada, et al., Cell Injury Unmasks a Latent Proangiogenic Phenotype in Mice With Increased Expression of FGF2 in the Retina, J. of Celluar Physiology; Oct. 2000; 185(1); pp. 135-142.
Badorc Alain
Bono Francoise
Bordes Marie-Francoise
Foidart Jean-Michel
Guillo Nathalie
Bolcsak James W.
Henley III Raymond
Ort Ronald G.
Sanofi-Aventis
LandOfFree
Use of FGF inhibiting substituted 1,2,3 indolizine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of FGF inhibiting substituted 1,2,3 indolizine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of FGF inhibiting substituted 1,2,3 indolizine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291598